U.S. Luxury Stock News

Those holding Olaplex Holdings, Inc. ( NASDAQ:OLPX ) shares would be relieved that the share price has rebounded 27% in...

Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have had a really impressive month, gaining 27% after a shaky period...

Deckers Outdoor Corporation ( NYSE:DECK ) shareholders are no doubt pleased to see that the share price has bounced 26...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Key Insights Institutions' substantial holdings in First Bank implies that they have significant influence over the...

Some SkyWest, Inc. ( NASDAQ:SKYW ) shareholders may be a little concerned to see that the Independent Director...

Wondering if Dolby Laboratories at around $66.62 is quietly turning into a value opportunity, or just a classic value trap in the making? The stock is down 14.4% year to date and 12.9% over the last year, even though it has inched up about 1.6% over the past month. This combination often signals shifting market expectations rather than a simple growth story. Recently, investors have been refocusing on Dolby's role as the audio and imaging standard across cinemas, streaming platforms, and...

In October 2025, Rayonier Inc. declared a special dividend of US$1.40 per common share, which was paid on December 12, 2025, and subsequently filed an omnibus shelf registration covering multiple securities, including debt, common and preferred shares, warrants, subscription rights, stock purchase contracts, and units. This combination of an immediate cash return to shareholders and expanded flexibility to raise capital in the future reflects Rayonier’s twin focus on rewarding investors...

Xenia Hotels & Resorts recently completed a major share repurchase program, buying back 3,717,939 shares for US$48.91 million between July 1 and December 4, 2025, and in total retiring 28,230,533 shares for US$377.5 million since the program began in 2015. By shrinking its share count by over a quarter through this long-running buyback, the company has materially increased each remaining investor’s claim on future cash flows and earnings. We’ll now examine how completing this extensive...

In recent days, Dimerix announced that its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis completed recruitment and dosing of 286 adult patients, while Amicus Therapeutics drew fresh attention after new analyst coverage highlighted the company’s earnings potential. Together, the late-stage progress of DMX-200 and the wave of optimistic research coverage sharpen the focus on Amicus’s pipeline depth and prospects for earnings improvement. Now we’ll examine how this...

Udemy (UDMY) just deepened its bet on AI driven upskilling by pairing a new microlearning experience with a fresh partnership with LG CNS that opens doors to hundreds of Korean enterprises and millions of professionals. See our latest analysis for Udemy. Those AI focused partnerships and product launches are landing against a tough backdrop, with Udemy’s share price return down sharply over the year and its three year total shareholder return still deeply negative. This suggests sentiment has...

If you are wondering whether Solstice Advanced Materials is still flying under the radar or already priced for perfection, you are not alone. This stock has quietly moved onto many watchlists. In the last week the share price has climbed 4.5%, and over the past 30 days it is up a solid 12.0%, even though year to date it is only slightly ahead at 0.8%. Much of that recent momentum has followed upbeat commentary around demand for next generation battery materials and new supply agreements with...

Wondering if ALLETE is still a quietly reliable value play in a choppy utilities market, or if most of the upside has already been priced in? This breakdown is for investors who care less about headlines and more about what the numbers actually say. The stock has inched up about 0.6% over the last week and month, and is up 4.6% year to date, while longer term investors have seen gains of 8.6% over 1 year, 20.4% over 3 years, and 44.3% over 5 years. This reflects a steady climb that suggests...

Cardinal Infrastructure Group (CDNL) jumped about 17% in the latest session, catching investors attention after a stretch of quiet trading and raising fresh questions about what the market is pricing into this construction contractor. See our latest analysis for Cardinal Infrastructure Group. The move takes Cardinal’s share price to about $29.65, and that 17.15% one day share price return builds on a solid 26.17% year to date share price return. This hints that momentum is picking up as...

National Beverage (FIZZ) just posted a quarter where sales and case volume slipped, even as pricing and mix nudged profits higher. It was a mixed update that helps explain the recent pressure on the stock. See our latest analysis for National Beverage. Investors have been reassessing that resilience, with the share price at $33.85 and a year to date share price return of negative 20.17% alongside a 12 month total shareholder return of negative 27.03%. This suggests momentum is still fading...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

As the U.S. stock market grapples with volatility, driven by concerns over an AI bubble impacting technology stocks and recent interest rate decisions by the Federal Reserve, investors are keenly observing economic indicators for guidance. In such fluctuating conditions, identifying undervalued stocks becomes crucial as they can offer potential opportunities for growth when trading below their intrinsic value amidst broader market uncertainties.

With a price-to-sales (or "P/S") ratio of 1.1x Celularity Inc. ( NASDAQ:CELU ) may be sending very bullish signals at...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

MGE Energy, Inc. ( NASDAQ:MGEE ), might not be a large cap stock, but it saw significant share price movement during...

Many investors define successful investing as beating the market average over the long term. But in any portfolio...

Key Insights Scinai Immunotherapeutics to hold its Annual General Meeting on 22nd of December Total pay for CEO Amir...

On December 4, 2025, TriMas Corporation announced that its Board appointed long-time company veteran Paul Swart as Chief Financial Officer and principal accounting officer, effective December 15, 2025, succeeding interim CFO and current board member Teresa Finley. Investors may view Swart’s return as important because he combines two decades of prior TriMas experience with recent external leadership overseeing acquisitions, financial transformation, and integration. We’ll now examine how...

In December 2025, the U.S. stock market is experiencing a mixed landscape, with the Dow Jones Industrial Average reaching new highs before retreating, while tech-heavy indices like the Nasdaq and S&P 500 face pressures due to AI bubble concerns. Amid these fluctuations, small-cap stocks in the United States present intriguing opportunities for investors seeking value in a volatile environment. Identifying potential growth within this segment requires careful consideration of economic...